Steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 November 2003 please refer to module 8B. 
•  On 3 December 2001, the Marketing Authorisation Holder submitted to the EMEA one application 
for  a  Type  I  variation  related  to  a  change  in  the  manufacturer  of  the  active  substance 
(EMEA/H/C/390/I/01). The EMEA approved this variation on 6 February 2002. 
•  The MAH submitted on 30 January 2002 a request to introduce changes to an aspect of the Package 
Leaflet  not  connected  to  the  SPC,  in  accordance  with  Article  61(3)  of  Council  Directive  No 
2001/83/EC.  This  change  concerned  an  update  to  the  contact  details  of  one  of  the  local 
representatives and to amend some typographical errors in the German Package Leaflet. The MAH 
received a positive notification from the EMEA on 5 February 2002. 
•  On  30  January  2002  the  Marketing  Authorisation  Holder  submitted  a  Corrigendum  to  the 
Commission  Decision  dated  27  November  2001  for  the  French  SPC  (section  5.1),  Finnish  SPC 
(section 5.1) and Swedish SPC (section 5.1) and the German labelling. This Corrigendum required 
amendments to the relevant sections of the Commission Decision.  
•  On 10 May 2002, the Marketing Authorisation Holder submitted to the EMEA one application for 
a Type  I variation  related  to  a  change  in specifications of the active substance and  consequential 
changes in test procedure of the active substance (EMEA/H/C/390/I/03). The EMEA approved this 
variation on 27 June 2002. 
•  On 12 June 2002, the Marketing Authorisation Holder submitted to the EMEA one application for 
a  Type  I  variation  related  to  a  change  in  the  manufacturer  of  the  active  substance 
(EMEA/H/C/390/I/04). The EMEA approved this variation on 17 July 2002. 
•  On 26 June 2002, the Marketing Authorisation Holder submitted to the EMEA an application for a 
Type  II  variation  (EMEA/H/C/390/II/05).  The  Marketing  Authorisation  Holder  applied  for  an 
update  of  section  4.4  of  the  Summary  of  Product  Characteristics  and  sections  2  and  4  of  the 
Package Leaflet following the first annual assessment of the Follow-up Measure with respect to iris 
colour  changes.  Furthermore,  the  MAH  applied  for  linguistic  changes  to  the  French,  Italian  and 
Dutch  Product  Information.  The  CPMP  considered  the  variation  acceptable  and  issued  on  22 
August 2002 a positive Opinion on the Type II variation. The corresponding Commission Decision 
was issued on 12 November 2002. 
•  On 9 December 2002, the Marketing Authorisation Holder submitted to the EMEA an application 
for  a  Type  I  variation  to  extend  the  shelf  life  of  the  finished  product  from  2  to  3  years 
(EMEA/H/C/390/I/07). The EMEA approved this variation on 10 January 2003. 
•  On 9 December 2002, the Marketing Authorisation Holder submitted to the EMEA an application 
for a Type II variation (EMEA/H/C/390/II/06). The Marketing Authorisation Holder applied for an 
extension  of  indication  for  TRAVATAN  to  be  used  as  first  line  therapy  in  patients  with  ocular 
hypertension  and  open-angle  glaucoma.  The  Marketing  Authorisation  Holder  also  applied  for 
amendments  to  the  Package  Leaflet  concerning  the  instructions  to  the  patient  in  relation  to 
discontinuation  and  use.  Furthermore,  the  term  “watery  eyes”  was  added  to  section  4  of  the 
Package Leaflet to harmonise with the Summary of Product Characteristics. The contact details of 
the Icelandic local representative were updated in the Package Leaflet. The CPMP considered the 
variation acceptable and issued on 25 April 2003 a positive Opinion on the Type II variation. The 
corresponding Commission Decision was issued on 28 July 2003. 
•  On 16 April 2003, the Marketing Authorisation Holder submitted to the EMEA an application for a 
the  active  substance 
Type  I  variation 
(EMEA/H/C/390/I/08). The EMEA approved this variation on 19 May 2003. 
the  manufacturer  of 
the  name  of 
to  change 
•  On  4  August  2003  the  Marketing  Authorisation  Holder  submitted  a  Corrigendum  to  the 
Commission Decision dated 28 July 2003 for the Dutch, French and Spanish SPC (sections 4.1, 4.4 
and  4.8.).  This  Corrigendum  required  amendments  to  the  relevant  sections  of  the  Commission 
Decision. 
1/2 

EMEA 2004 
 
 
 
 
 
 
•  On 16 May 2003, the Marketing Authorisation Holder submitted to the EMEA an application for a 
Type  II  variation  (EMEA/H/C/390/II/09).  The  Marketing  Authorisation  Holder  applied  for  an 
update  of  section  4.8  of  the  Summary  of  Product  Characteristics  and  sections  2  and  4  of  the 
Package  Leaflet  following  the  assessment  of  the  second  Periodic  Safety  Update Report  (PSUR). 
The CPMP considered the variation acceptable and issued on 24 July 2003 a positive Opinion on 
the Type II variation. The corresponding Commission Decision was issued on 24 October 2003. 
2/2 

EMEA 2004 
 
 
 
 
 
 
 
